Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + bevacizumab + pemetrexed + carboplatin
- Development stage
- Unknown
- Lead developer
- Hunan Cancer Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This investigational treatment regimen is being evaluated in a Phase 2 clinical trial (NCT05266846) at the Hunan Province Tumor Hospital for the treatment of metastatic ALK fusion-positive non-small cell lung cancer (NSCLC) in patients who have progressed after first-line alectinib therapy. The regimen consists of the anti-PD-1 monoclonal antibody pembrolizumab, the anti-VEGF monoclonal antibody bevacizumab, and a chemotherapy backbone of pemetrexed and carboplatin. By combining immunotherapy, anti-angiogenic therapy, and cytotoxic chemotherapy, the regimen aims to overcome resistance to ALK tyrosine kinase inhibitors (TKIs) and improve outcomes in advanced lung adenocarcinoma with persistent 5'ALK.
- Other names
- chemotherapy + bevacizumab-Hunan Province Tumor Hospital-non-small cell lung cancerPembrolizumab plus Bevacizumab plus Pemetrexed plus CarboplatinChemotherapy plus Immune Checkpoint Inhibitors with or without Bevacizumab
02
Targets
VEGFA (Vascular endothelial growth factor A)DHFR (Dihydrofolate reductase)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)DNATS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + bevacizumab + pemetrexed + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + bevacizumab + pemetrexed + carboplatin.